TNFSF13B and neoplasm: This identified tumour cell-reactive antibodies from B cells stimulated with IL-17+BAFF+CpG in 51 of 1800 wells (2.8%) tested, and in 27 out of 1800 wells (1.5%) of B cells stimulated with CpG alone (Fig. 5, Table 1).